GAITHERSBURG, Md., March 28 Iomai Corporation(Nasdaq: IOMI) today announced, in compliance with NASDAQ marketplace rules,that the independent audit report included in the Company's Annual Report onForm 10-K filed with the Securities and Exchange Commission on March 27, 2008for the fiscal year ended December 31, 2007 contained a "going concern"qualification. This disclosure is required under NASDAQ marketplace rules anddoes not represent any change to the Company's Annual Report on Form 10-K forthe year ended December 31, 2007 and filed on March 27, 2008 with the SEC.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune systemstimulants, delivered via a novel, needle-free technology calledtranscutaneous immunization (TCI). TCI, discovered by researchers at theWalter Reed Army Institute of Research, taps into the unique benefits of amajor group of antigen-presenting cells found in the outer layers of the skin(Langerhans cells) to generate an enhanced immune response. Iomai isleveraging TCI to enhance the efficacy of existing vaccines, develop newvaccines that are viable only through transcutaneous administration and expandthe global vaccine market. Iomai currently has four product candidates indevelopment: three targeting influenza and pandemic flu and one to preventtravelers' diarrhea. For more information on Iomai, please visithttp://www.iomai.com.
SOURCE Iomai Corporation